OBSOLETE: Oculocerebroacral syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2706
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Oculocerebroacral syndrome, also sometimes referred to as Kaufman oculocerebrofacial syndrome, is an extremely rare genetic condition that was described in only a very small number of patients in the medical literature. The term is now considered obsolete in some classification systems, meaning it may have been reclassified or merged with another recognized condition. This syndrome was reported to affect multiple body systems, particularly the eyes (oculo-), the brain (cerebro-), and the limbs or extremities (acral). Patients described with this condition had a combination of eye abnormalities, intellectual disability or developmental delays, and abnormalities of the hands and feet. Facial features that appeared distinctive were also noted in some cases. Because so few individuals were ever reported, the full range of symptoms and the natural history of this condition remain poorly understood. There is no specific targeted treatment; management has been supportive and focused on addressing individual symptoms such as vision problems, developmental delays, and any structural abnormalities. Families affected by this condition should work closely with a clinical geneticist to clarify the diagnosis, as advances in genetic testing may now allow a more precise classification of the underlying cause.

Key symptoms:

Eye abnormalities such as small eyes (microphthalmia)Intellectual disability or developmental delayAbnormalities of the fingers or toesDistinctive facial featuresShort stature or growth delayLow muscle tone (floppiness)Delayed speech developmentDelayed motor milestones such as sitting and walkingPossible structural brain abnormalitiesVision problems

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Oculocerebroacral syndrome.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Oculocerebroacral syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Oculocerebroacral syndrome community →

No specialists are currently listed for OBSOLETE: Oculocerebroacral syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Oculocerebroacral syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Oculocerebroacral syndromeForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Oculocerebroacral syndrome.

Start the conversation →

Latest news about OBSOLETE: Oculocerebroacral syndrome

No recent news articles for OBSOLETE: Oculocerebroacral syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Has modern genetic testing been done to confirm or reclassify this diagnosis?,What specific therapies would benefit my child's development the most right now?,How often should my child have eye examinations and brain imaging?,Are there any clinical trials or research studies we could participate in?,What educational supports should we request for my child at school?,Should other family members be tested to understand the inheritance pattern?,What specialists should be part of my child's ongoing care team?

Common questions about OBSOLETE: Oculocerebroacral syndrome

What is OBSOLETE: Oculocerebroacral syndrome?

Oculocerebroacral syndrome, also sometimes referred to as Kaufman oculocerebrofacial syndrome, is an extremely rare genetic condition that was described in only a very small number of patients in the medical literature. The term is now considered obsolete in some classification systems, meaning it may have been reclassified or merged with another recognized condition. This syndrome was reported to affect multiple body systems, particularly the eyes (oculo-), the brain (cerebro-), and the limbs or extremities (acral). Patients described with this condition had a combination of eye abnormalities

How is OBSOLETE: Oculocerebroacral syndrome inherited?

OBSOLETE: Oculocerebroacral syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does OBSOLETE: Oculocerebroacral syndrome typically begin?

Typical onset of OBSOLETE: Oculocerebroacral syndrome is neonatal. Age of onset can vary across affected individuals.